[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Amicus Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":186},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,45,69,89,113,134,146,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100585584","phase-3-a-study-of-migalastat-in-pediatric-subjects-2-to-12-yrs-with-fabry-disease-and-amenable-gla-variants-100585584",false,"NCT06904261","A Study of Migalastat in Pediatric Subjects (2 to \u003C12 Yrs) With Fabry Disease and Amenable GLA Variants","An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Treatment With Migalastat in Pediatric Subjects (Aged 2 to \u003C 12 Years) With Fabry Disease and Amenable GLA Variants","Inclusion Criteria\n\n* Male or female subjects, diagnosed with Fabry disease who are between ages 2 and \\\u003C 12 years at randomization (subjects aged 11 years must have birthdays \\> 30 days after randomization)\n* Subject's parent or legally authorized representative is willing and able to provide written informed consent and authorization for use and disclosure of personal health information or research-related health information, and subject provides assent, if applicable.\n* Subject has a GLA variant documented in his\u002Fher medical record that is amenable to migalastat prior to Visit 2.\n* Subject has not received ERT (eg, Replagal® \\[agalsidase alfa\\] or Fabrazyme® \\[agalsidase beta\\]) for at least 14 days prior to Baseline visit.\n* Subject has at least 1 documented complication (ie, historical or current laboratory abnormality or sign\u002Fsymptom) of Fabry disease\n* If of reproductive potential, both male and female subjects agree to use a medically accepted method of contraception throughout the duration of the study and for up to 30 days after their last dose of migalastat.\n\nExclusion Criteria\n\n* Has moderate or severe renal impairment (eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m2 at Visit 1 \\[screening\\]).\n* Has advanced kidney disease requiring dialysis or kidney transplantation.\n* History of allergy or sensitivity to migalastat (including excipients) or other iminosugars (eg, miglustat, miglitol).\n* Has received any investigational\u002Fexperimental drug, biologic, or device within 30 days or 5 half-lives of the investigational product (whichever is longer) before Visit 1 (screening).\n* Has received any gene therapy at any time or anticipates starting gene therapy during the study period.\n* Requires treatment with Glyset (miglitol) or Zavesca (miglustat), within 6 months before Visit 1(screening) or throughout the study.\n* Has any intercurrent illness or condition at Visit 1 (screening) or Visit 2 (baseline) that may preclude the subject from fulfilling the protocol requirements or suggests to the investigator that the potential subject may have an unacceptable risk by participating in this study.\n* Pregnant or breastfeeding\n* Otherwise unsuitable for the study in the opinion of the investigator","ALL","2 Years","11 Years",{"count":5,"type":20},"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","An open-label study to evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of migalastat treatment in pediatric subjects 2 to \\\u003C 12 years of age with Fabry disease and with amenable GLA variants.",[26],"Fabry Disease",[28,29,30,31],"migalastat","AT1001","Galafold","lysosomal disease","RECRUITING","2026-06-23",{"date":35,"type":36},"2026-06-25","ACTUAL",{"date":38,"type":36},"2026-01-08",{"date":40,"type":20},"2028-12",{"name":42,"class":43},"Amicus Therapeutics","INDUSTRY",11,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":5},"100585745","a-study-of-patients-with-fabry-disease-us-specific-100585745","NCT06906367","A Study of Patients With Fabry Disease (US Specific)","A Prospective, Observational Study of Patients With Fabry Disease (US Specific)","I. Migalastat-treated patients (Commercial only participants)\n\n1. Patients with Fabry disease 18 years or older with amenable GLA variants who have commenced commercial migalastat treatment within 24 months preceding enrollment, who have an eGFR greater than or equal to 30 mL\u002Fmin\u002F1.73 m2 at the time of enrollment and are still taking migalastat at the time of enrollment, or who are starting migalastat at the time of enrollment, excluding those who participated in a prior migalastat clinical trial\n2. Patients who show a decline in their Fabry disease symptomatology based on any of the following:\n\n   1. a decrease in annualized rate of decline eGFRCKD-EPI of ≥ 2 mL\u002Fmin\u002F1.73 m2 during the 2 years prior to enrollment\n   2. microalbuminuria\u002Fmacroalbuminuria (≥ 30 mg\u002F24 h or ≥ 20 mg on first morning urine) or urine ACR of ≥ 30 mg\u002Fg (via spot urine collection) at any time prior to or at enrollment\n   3. proteinuria (\\> 0.5 g\u002Fg UPCR) any time prior to or at enrollment\n   4. males with classic Fabry disease phenotype\n\nII. Migalastat-treated patients who are not considered to be in renal decline (Commercial migalastat users only)\n\n1\\. Patients with Fabry disease with amenable GLA variants who have been on commercial migalastat regardless of the duration of treatment\n\nIII. Migalastat-treated patients (Prior clinical trial participants)\n\n1. Patients with Fabry disease 18 years or older who had commenced treatment with migalastat while in a clinical trial and were exposed to treatment for at least 24 months preceding enrollment, who have an eGFR greater than or equal to 30 mL\u002Fmin\u002F1.73 m2 at the time of enrollment, and who are still taking migalastat at the time of enrollment, having switched to commercial product\n\nIV. Untreated patients\n\n1. Patients with Fabry disease 18 years or older with amenable GLA variants, who have never been on treatment for Fabry disease, who have an eGFR greater than or equal to 30 mL\u002Fmin\u002F1.73 m2 at the time of enrollment, and who meet local treatment guidelines for Fabry disease\n2. Patients who show a decline in their Fabry disease symptomatology based on any of the following:\n\n   1. a decrease in annualized rate of decline eGFRCKD-EPI of ≥ 2 mL\u002Fmin\u002F1.73 m2 during the 2 years prior to enrollment\n   2. microalbuminuria\u002Fmacroalbuminuria (≥ 30 mg\u002F24 h or ≥ 20 mg on first morning urine) or urine ACR of ≥ 30 mg\u002Fg (via spot urine collection) at any time prior to or at enrollment\n   3. proteinuria (\\> 0.5 g\u002Fg UPCR) any time prior to or at enrollment\n   4. males with classic Fabry disease phenotype\n\nV. ERT-treated patients\n\n1. Patients with Fabry disease 18 years or older who have commenced ERT within 24 months preceding enrollment, who have an eGFR greater than or equal to 30 mL\u002Fmin\u002F1.73 m2 at the time of enrollment and are still being treated with ERT at the time of enrollment, and who have amenable GLA variants\n2. Patients who show a decline in their Fabry disease symptomatology based on any of the following:\n\n   1. a decrease in eGFRCKD-EPI annualized rate of decline of ≥ 2 mL\u002Fmin\u002F1.73 m2 during the 2 years prior to enrollment\n   2. microalbuminuria\u002Fmacroalbuminuria (≥ 30 mg\u002F24 h or ≥ 20 mg on first morning urine) or urine ACR of ≥ 30 mg\u002Fg (via spot urine collection) at any time prior to or at enrollment\n   3. proteinuria (\\> 0.5 g\u002Fg UPCR) any time prior to or at enrollment\n   4. males with classic Fabry disease phenotype\n\nAll patients 1. All treated and untreated patients with Fabry disease who are enrolled in the study must be able to understand and provide written informed consent or assent.\n\nExclusion Criteria\n\n1\\. Patients who currently are participating in a clinical trial of any investigational medicinal product or device at the time of enrollment","18 Years",{"count":54,"type":20},450,"5 Years","OBSERVATIONAL","This is an observational study to evaluate the effects of treatment on long-term effectiveness, safety, and health-related quality of life (HRQOL) in patients with Fabry disease, with a main focus on migalastat.",[26],[28,29,60,31],"registry","2026-05-14",{"date":63,"type":36},"2026-05-18",{"date":65,"type":36},"2026-02-13",{"date":67,"type":20},"2032-06",{"name":42,"class":43},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":75,"targetDuration":55,"studyType":56,"phases":4,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100525382","a-global-prospective-observational-registry-of-patients-with-pompe-disease-100525382","NCT06121011","A Global Prospective Observational Registry of Patients With Pompe Disease","Inclusion Criteria:\n\n* Diagnosis of LOPD or IOPD based on documented deficiency of GAA enzyme activity and\u002For GAA genotyping\n\nExclusion Criteria:\n\n* Patients who are currently receiving investigational therapy for Pompe disease in a clinical trial, a compassionate use program, or an expanded access program (EAP)",{"count":76,"type":20},500,"This is a global, multicenter, prospective, observational registry of patients with Pompe disease, including those with late-onset pompe disease (LOPD) and infantile-onset pompe disease (IOPD). Both untreated patients and those being treated with an approved therapy for Pompe disease are eligible to participate.\n\nThe objectives of the registry are:\n\n* To evaluate the long-term safety of Pompe disease treatments through collection of data that describe the frequency of adverse events (AEs)\u002Fserious adverse events (SAEs) occurring in Pompe disease patients\n* To evaluate the long-term real-world effectiveness of Pompe disease treatments\n* To evaluate the long-term real-world impact of Pompe disease treatments on quality of life (QOL) and patient-reported outcomes (PROs)\n* To describe the natural history of untreated Pompe disease",[79],"Pompe Disease","2026-03-09",{"date":82,"type":36},"2026-03-10",{"date":84,"type":36},"2024-02-16",{"date":86,"type":20},"2034-12-20",{"name":42,"class":43},41,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":21,"phases":100,"briefSummary":101,"conditions":102,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100424561","phase-3-a-study-to-evaluate-the-safety-efficacy-pk-pd-and-immunogenicity-of-cipaglucosidase-alfamiglustat-in-iopd-subjects-aged-0-to-18-100424561","NCT04808505","A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa\u002FMiglustat in IOPD Subjects Aged 0 to \u003C18","An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Cipaglucosidase Alfa\u002FMiglustat in Both ERT-experienced and ERT-naïve Pediatric Subjects With Infantile-onset Pompe Disease Aged 0 to \u003C 18 Years","ROSSELLA","Inclusion Criteria:\n\nCohort 1:\n\n1. Male or female subjects who are aged 6 months to \\\u003C 18 years on Day 1\n2. Subject must have documentation of IOPD genotype\n3. Subject must have had hypertrophic cardiomyopathy at the time of diagnosis\n4. Subject must have received ERT for at least 6 months immediately before enrollment. For subjects whose ERT dosage has been modified, the subject must have been on the modified dosage and regimen for at least 3 months before enrollment\n5. Subjects aged ≥ 12 to \\\u003C 18 years must perform one valid 6-minute walk test (6MWT) (≥ 75 meters) at screening; Subjects aged ≥ 5 to \\\u003C 12 years must perform one valid 6MWT (≥ 40 meters) at screening; Subjects aged 18 months to \\\u003C 5 years must be ambulatory and assessed to be likely to be able to perform 6MWT (≥ 40 meters) when they turn 5 years old\n6. Subjects must have experienced a clinical decline on their current rhGAA dose and frequency\n\nCohort 2:\n\n1. Male or female subjects who are aged 0 to \\\u003C6 months at Day 1\n2. Subject must have documentation of IOPD genotype\n3. Subject must have had hypertrophic cardiomyopathy at the time of diagnosis\n4. Subject is ERT-naïve\n\nLong-term Extension (Cohort 1 or Cohort 2):\n\n1\\. Subject must have, in the opinion of the investigator, benefited from therapy with cipaglucosidase alfa\u002Fmiglustat during the 104-week primary treatment period with no significant safety concerns.\n\nExclusion Criteria:\n\nCohort 1 and Cohort 2, unless specified\n\n1. Subject requires invasive ventilation (eg, tracheostomy)\n2. Subject is CRIM negative and has not received prophylactic immunomodulation (Cohort 1); Subject is CRIM negative and will not be receiving prophylactic immunomodulation (Cohort 2)\n3. Subject has a history of life-threatening IARs\u002Fhypersensitivity (eg, anaphylaxis and severe cutaneous reactions) to ERT (eg, alglucosidase alfa, cipaglucosidase alfa, miglustat) or other iminosugars, or to any of the excipients, where rechallenge was unsuccessful\n4. Subject has prior history of illness or condition known to affect motor function\n5. Female subject is pregnant (or intends to get pregnant) or breastfeeding at screening (Cohort 1)","17 Years",{"count":99,"type":20},36,[23],"This is a Phase 3, open-label, multicenter study to evaluate the safety, efficacy, PK, PD, and immunogenicity of cipaglucosidase alfa\u002Fmiglustat treatment in ERT-experienced and ERT-naïve pediatric subjects with IOPD.",[103],"Glycogen Storage Disease Type II Infantile Onset","2026-01-20",{"date":106,"type":36},"2026-01-22",{"date":108,"type":36},"2023-07-18",{"date":110,"type":20},"2027-07",{"name":42,"class":43},14,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":120,"maxAge":97,"enrollmentInfo":4,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":132,"locationsCount":133},"100387687","expanded-access-for-atb200at2221-for-the-treatment-of-iopd-100387687","NCT04327973","Expanded Access for ATB200\u002FAT2221 for the Treatment of IOPD","Expanded Use Of Recombinant Human Acid Alpha-Glucosidase\u002FN-butyl-deoxynojirimycin (ATB200\u002FAT2221) For Patients With Infantile-Onset Pompe Disease","Inclusion Criteria:\n\n1. Patient is male or female and 0 to \\\u003C 18 years old.\n2. Patient has a diagnosis of Pompe disease, based on documentation of GAA genotyping demonstrating variants associated with IOPD.\n3. Patient does not currently qualify for or is unable to enroll (eg, due to location, etc) in any commercial drug-sponsored ongoing clinical trial.\n4. Patient is currently being treated with an approved ERT and is declining (eg, worsening in motor function, respiratory function\u002Fparameters, cardiac function, etc) based on treating physician's clinical judgement.\n5. The patient's legal guardian or representative has given informed consent (and assent when age appropriate for regional requirements) to treatment prior to administering ATB200\u002FAT2221 in a manner consistent with all national requirements.\n6. If of reproductive potential and sexually active, female subjects agree to use a highly effective method of contraception throughout the duration of the treatment and for up to 90 days after their last dose of ATB200\u002FAT2221.\n\nExclusion Criteria:\n\n1. Patient has a hypersensitivity to any of the excipients in ATB200, alglucosidase alfa, or AT2221\n2. Patient has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator and\u002For Amicus, pose an undue safety risk to the patient.\n3. Concomitant use of miglitol (eg, Glyset), non-AT2221 form of miglustat (eg, Zavesca), acarbose (eg, Precose or Glucobay), voglibose (eg, Volix, Vocarb,or Volibo)","0 Years","EXPANDED_ACCESS","This is an expanded access program (EAP) for eligible participants designed to provide access to ATB200\u002FAT2221.",[124],"Pompe Disease Infantile-Onset",[126,127],"expanded access","compassionate use","AVAILABLE","2025-09-09",{"date":131,"type":36},"2025-09-10",{"name":42,"class":43},4,{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":122,"conditions":141,"keywords":142,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":143,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":145,"locationsCount":4},"100352205","expanded-access-for-atb200at2221-for-the-treatment-of-pompe-disease-100352205","NCT03865836","Expanded Access for ATB200\u002FAT2221 for the Treatment of Pompe Disease","Named Patient or Compassionate Use for Treatment Use of ATB200\u002FAT2221 for Patients With Pompe Disease","Inclusion Criteria:\n\n1. Subject must have a diagnosis of Pompe disease based on documentation of one of the following:\n\n   1. deficiency of GAA enzyme\n   2. GAA genotyping\n2. Patient does not currently qualify for an Amicus sponsored on-going clinical trial or is declining on currently approved ERT (e.g. Myozyme)\n3. The patient must be willing to receive treatment with ATB200\u002FAT2221 via this program, which includes signing an authorization form for sharing clinical data with Amicus Therapeutics, and its agent Early Access Care LLC.\n\nExclusion Criteria:\n\n1. Patient, whether male or female, is planning to conceive a child during the treatment program.\n2. Patient has a hypersensitivity to any of the excipients in ATB200, alglucosidase alfa, or AT2221\n3. Patient has a medical or any other extenuating condition or circumstance that may, in the opinion of the investigator, pose an undue safety risk to the subject or compromise his\u002Fher ability to comply with or adversely impact protocol requirements.\n4. Patient has received any gene therapy at any time.\n5. Concomitant use of miglitol (eg, Glyset), non-AT2221 form of miglustat (eg, Zavesca), acarbose (eg, Precose or Glucobay), voglibose (eg, Volix, Vocarb, or Volibo)",[79],[126,127],{"date":144,"type":36},"2025-09-15",{"name":42,"class":43},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":152,"minAge":4,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},"100381857","a-global-prospective-observational-study-of-women-with-fabry-disease-and-their-infants-during-pregnancy-and-breastfeeding-100381857","NCT04252066","A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding","Inclusion Criteria:\n\nFemale patients meeting the following criteria will be eligible for study enrollment:\n\n1. Patients with Fabry disease who are pregnant and\u002For breastfeeding, whether or not they are exposed to migalastat\n2. Able and willing to provide informed consent or assent, if applicable.\n3. Able and willing to provide HCP contact information.\n\nExclusion Criteria:\n\nNone","FEMALE",{"count":154,"type":20},20,"This is a global prospective observational study of women with Fabry disease and their infants during pregnancy and\u002For breastfeeding. The study will evaluate outcomes of pregnancy and\u002For breastfeeding in women and infants exposed to migalastat.",[26],[28,26,158],"Women with Fabry Disease","2025-07-02",{"date":161,"type":36},"2025-07-08",{"date":163,"type":36},"2025-03-18",{"date":165,"type":20},"2030-02",{"name":42,"class":43},1,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":121,"phases":4,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":128,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":185,"locationsCount":4},"100169205","physician-initiated-expanded-access-request-for-migalastat-in-individual-patients-with-fabry-disease-100169205","NCT01476163","Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease","Physician Initiated Expanded Access Request for Treatment Use of Migalastat Hydrochloride (AT1001), an Investigational Treatment for Individual Patients With Fabry Disease (AT1001-188)","Inclusion Criteria:\n\n* Confirmed GLA mutation predicted to be responsive migalastat in the human embryonic kidney (HEK-293) cell-based assay\n* At least 2 years of age\n* Strong clinical indication for treatment of Fabry disease\n* No other treatment option including either unsuitable for ERT or unable to access ERT\n* Appropriate female and male contraception\n* Willing to receive treatment with migalastat HCl via this program including having signed an authorization for sharing clinical data\n\nExclusion Criteria:\n\n* Scheduled for renal or other organ transplant or replacement therapy\n* Receiving GLYSET® (miglitol), ZAVESCA® (miglustat) or enzyme replacement therapy FABRAZYME® (agalsidase beta), REPLAGAL™ (agalsidase alpha), or Elfabrio® (pegunigalsidase alfa)\n* Contraindication to migalastat, i.e., sensitivity to other iminosugar such as miglustat, miglitol\n* Treated with another investigational drug within 30 days of start of migalastat HCl treatment\n* Unable to comply with study requirements or deemed otherwise unsuitable for study entry in the opinion of the investigator.","This program allows physicians to request permission from Amicus Therapeutics (Amicus) for treatment access to migalastat hydrochloride (HCl) for specific patients with Fabry disease. Treatment is open label.",[26],[29,28,178,179,180,31,181],"Fabry disease","Fabry","Amicus","lysosomal disorder","2025-07-01",{"date":184,"type":36},"2025-07-03",{"name":42,"class":43},""]